I keep finding all of these falling wedges lolPure call option short term pump.
This is at long term support and can make the turning point for either direction. I would play the move prior to earnings which I think will be a pump to the red resistance.
IF IT DOES hit my levels, be prepared for a rug pull at earnings for buy rumor and sell
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.544 EUR
−191.15 M EUR
754.78 M EUR
104.60 M
About Apellis Pharmaceuticals, Inc.
Sector
Industry
CEO
Cedric Francois
Website
Headquarters
Waltham
Founded
2009
FIGI
BBG01TNWBDG1
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
APLS5052553
Apellis Pharmaceuticals, Inc. 3.5% 15-SEP-2026Yield to maturity
−3.02%
Maturity date
Sep 15, 2026
See all 1APLS bonds
Related stocks
Frequently Asked Questions
The current price of 1APLS is 17.436 EUR — it has decreased by −2.60% in the past 24 hours. Watch APELLIS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange APELLIS PHARMACEUTICALS INC stocks are traded under the ticker 1APLS.
1APLS stock has risen by 14.26% compared to the previous week, the month change is a 14.26% rise, over the last year APELLIS PHARMACEUTICALS INC has showed a 13.15% increase.
We've gathered analysts' opinions on APELLIS PHARMACEUTICALS INC future price: according to them, 1APLS price has a max estimate of 66.00 EUR and a min estimate of 18.48 EUR. Watch 1APLS chart and read a more detailed APELLIS PHARMACEUTICALS INC stock forecast: see what analysts think of APELLIS PHARMACEUTICALS INC and suggest that you do with its stocks.
1APLS reached its all-time high on May 2, 2025 with the price of 18.078 EUR, and its all-time low was 15.410 EUR and was reached on Apr 25, 2025. View more price dynamics on 1APLS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1APLS stock is 0.99% volatile and has beta coefficient of 0.96. Track APELLIS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is APELLIS PHARMACEUTICALS INC there?
Today APELLIS PHARMACEUTICALS INC has the market capitalization of 2.22 B, it has increased by 3.54% over the last week.
Yes, you can track APELLIS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
APELLIS PHARMACEUTICALS INC is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
1APLS earnings for the last quarter are −0.28 EUR per share, whereas the estimation was −0.36 EUR resulting in a 21.51% surprise. The estimated earnings for the next quarter are −0.33 EUR per share. See more details about APELLIS PHARMACEUTICALS INC earnings.
APELLIS PHARMACEUTICALS INC revenue for the last quarter amounts to 205.30 M EUR, despite the estimated figure of 192.03 M EUR. In the next quarter, revenue is expected to reach 179.30 M EUR.
1APLS net income for the last quarter is −35.12 M EUR, while the quarter before that showed −51.59 M EUR of net income which accounts for 31.94% change. Track more APELLIS PHARMACEUTICALS INC financial stats to get the full picture.
No, 1APLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 7, 2025, the company has 710 employees. See our rating of the largest employees — is APELLIS PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. APELLIS PHARMACEUTICALS INC EBITDA is −157.63 M EUR, and current EBITDA margin is −20.88%. See more stats in APELLIS PHARMACEUTICALS INC financial statements.
Like other stocks, 1APLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade APELLIS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.